Tunneled femoral central venous catheters in children with cancer.
OBJECTIVE
We discuss the feasibility of long-term femoral venous access by means of a cuffed subcutaneously tunneled central venous catheter (Broviac catheter) in selected pediatric cancer and stem cell transplant patients in whom access via the veins of the upper part of the torso is difficult or contraindicated and in whom alternative routes must be used.


METHODS
We report on our experience with 9 patients (3 of whom underwent stem cell transplantation) who received femoral Broviac catheters between December 1990 and November 1999. Results. Time in place ranged from 4 to 155 days with a median of 58 days (mean: 71.2 days). Three catheters had to be removed: 1 because of infection of the subcutaneous tunnel and 2 because of catheter obstruction. The remaining 6 catheters functioned well without problems as long as they were needed; 1 of them got accidentally dislodged while the patient was off treatment. No episodes of catheter-related septicemia, thrombosis, kinking, or drug extravasation were noted; there were no catheter-related infectious complications in the transplant patients.


CONCLUSIONS
Our experience indicates that in those instances in which customary access to the superior vena cava is precluded, long-term venous access by way of the femoral vein is a feasible and safe alternative in children, even in the setting of stem cell transplantation.
Sovinz
P
P
Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Graz, Auenbruggerplatz, Graz, Austria. petra.sovinz@klinikum-graz.at
Urban
C
C
Lackner
H
H
Kerbl
R
R
Schwinger
W
W
Dornbusch
H
H
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002405:Catheterization, Central Venous / Q000379:methods*; D002408:Catheters, Indwelling; D002648:Child; D002675:Child, Preschool; D005240:Feasibility Studies; D005268:Femoral Vein / Q000601:surgery*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000628:therapy*; D016748:Venous Cutdown / Q000379:methods
D000970:Antineoplastic Agents